MREO

Peers: RARE KRRO KROS ABEO LRMR WVE PLX ZVRA RZLT AKTX

Index	-
Market Cap	46.29M
Enterprise Value	17.20M
Income	-28.05M
Sales	0.00M
Book/sh	0.18
Cash/sh	0.19
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	39
IPO	Apr 24, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.62
P/C	1.54
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.88
Current Ratio	5.88
Debt/Eq	0.04
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.18
EPS next Y	-0.03
EPS next Q	-0.02
EPS this Y	-23.64%
EPS next Y	51.71%
EPS next 5Y	-9.90%
EPS past 3/5Y	8.97% 38.96%
Sales past 3/5Y	- -
EPS Y/Y TTM	44.94%
Sales Y/Y TTM	-100.00%
EPS Q/Q	52.76%
Sales Q/Q	-100.00%
Earnings	Aug 11 BMO
EPS/Sales Surpr.	-25.00% -100.00%

Insider Own	0.00%
Insider Trans	-
Inst Own	35.46%
Inst Trans	-6.38%
ROA	-57.62%
ROE	-67.72%
ROIC	-97.88%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.26%
SMA50	-5.07%
SMA200	-12.47%
Trades

Shs Outstand	159.62M
Shs Float	159.62M
Short Float	2.02%
Short Ratio	0.82
Short Interest	3.23M
52W High	2.37 -87.76%
52W Low	0.20 45.00%
Volatility	9.01% 8.90%
ATR (14)	0.03
RSI (14)	43.41
Beta	0.24
Rel Volume	0.00
Avg Volume	3.94M
Volume	54

Perf Week	5.45%
Perf Month	-23.64%
Perf Quarter	-9.97%
Perf Half Y	1.01%
Perf YTD	-30.41%
Perf Year	-84.74%
Perf 3Y	-85.99%
Perf 5Y	-88.07%
Perf 10Y	-
Recom	2.17
Target Price	2.00
Prev Close	0.29
Price	0.29
Change %	0.17%

Consensus

Buy

Avg. Price Target

$2.00

Implied Upside

+589.7%

Analysts6incl. previous ratings

Rating Distribution4 Buy · 1 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 19, 2026	Downgrade	JJP Morgan	Neutral → Underweight
Mar 23, 2026	Downgrade	JJP Morgan	Overweight → Neutral
Dec 30, 2025	Downgrade	JJefferies	Buy → Hold	$0.50	+72.4%
Mar 27, 2025	Initiated	JJP Morgan	Overweight	$7	+2,313.8%
Dec 06, 2024	Initiated	JJefferies	Buy	$7	+2,313.8%
Jun 13, 2024	Initiated	RRobert W. Baird	Outperform	$8	+2,658.6%
Oct 13, 2023	Resumed	BBTIG Research	Buy	$4	+1,279.3%
Aug 12, 2022	Initiated	CCantor Fitzgerald	Overweight	$4	+1,279.3%
May 05, 2021	Initiated	BBTIG Research	Buy	$10	+3,348.3%
Apr 05, 2021	Initiated	NNeedham	Buy	$10	+3,348.3%

Aug-12-26 05:43AM	Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat (Pharmaceutical Business Review)
Aug-11-26 08:15AM	Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights (GlobeNewswire) +12.15%
08:00AM	Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) (PR Newswire)
08:00AM	Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) (GlobeNewswire)
May-12-26 07:30AM	Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
01:13AM	Loading…
Mar-20-26 01:13AM	Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO (PR Newswire) -5.18%
Mar-19-26 08:30AM	Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Mar-18-26 09:05AM	LEVI & KORSINSKY, LLP: BONE MINERAL DENSITY CLAIMS CHALLENGED IN MEREO BIOPHARMA SECURITIES ACTION (PR Newswire) -6.21%
Mar-12-26 04:19AM	Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO (PR Newswire)
Mar-11-26 09:00AM	LEVI & KORSINSKY, LLP: CEO AND CSO NAMED AS CONTROL PERSON DEFENDANTS IN MEREO BIOPHARMA SECURITIES ACTION (PR Newswire)
Feb-25-26 09:00AM	LEVI & KORSINSKY, LLP: MEREO BIOPHARMA SECURITIES FILINGS ALLEGEDLY CONTAINED MISLEADING CLINICAL TRIAL DISCLOSURES (PR Newswire)
Feb-14-26 11:23AM	Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately (PR Newswire)
Feb-09-26 03:29AM	Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO (PR Newswire) -8.60%
Feb-06-26 07:30AM	Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MREO (Business Wire) +13.20%
Jan-12-26 08:00AM	Mereo BioPharma Provides Corporate Update (GlobeNewswire) +14.75%
09:40AM	Loading…
Dec-31-25 09:40AM	DigitalBridge downgraded, Commvault initiated: Wall Streets top analyst calls (TipRanks) +12.47%
Dec-30-25 12:39PM	Why Ultragenyx Stock Dropped 42% and What Comes Next (Barrons.com) +29.82%
11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
09:36AM	DigitalBridge downgraded, Commvault initiated: Wall Street's top analyst calls (The Fly)
Dec-29-25 01:05PM	These biotech stocks are getting hammered by shocking brittle-bone treatment study results (MarketWatch) -87.65%
08:31AM	Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Nov-10-25 04:01PM	Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire) +5.65%
Aug-19-25 08:30AM	ashibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2 (Business Wire)
Aug-12-25 07:35AM	Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire) +9.21%
Aug-11-25 07:45AM	Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 (Insider Monkey)
Jul-10-25 10:37AM	Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update (Barrons.com) -42.52%
10:34AM	Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease (Investor's Business Daily)
10:17AM	RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End (Zacks)
07:52AM	Kellogg shares soar on buyout talk, and other early market movers (MarketWatch)
Jul-09-25 04:05PM	Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis (GlobeNewswire)
07:30AM	Loading…
May-13-25 07:30AM	Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire) -7.20%
Apr-16-25 03:00PM	Mereo BioPharma Group plc (MREO): A Bull Case Theory (Insider Monkey) +6.50%
11:23AM	Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-26-25 07:30AM	Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Mar-20-25 12:00PM	MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-05-25 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-11-25 11:00AM	Mereo Insurance forays into reinsurance market (Life Insurance International)
Feb-10-25 02:12PM	Ex-AIG Chief Secures $700 Million for Mereo Reinsurance Startup (Bloomberg)
Jan-12-25 11:05AM	Mereo BioPharma Provides Update on Lead Clinical Programs (GlobeNewswire)
Jan-07-25 07:30AM	Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:50PM	Why Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey) -5.63%
Dec-07-24 05:20AM	Mereo BioPharma initiated with a Buy at Jefferies (TipRanks)
Dec-06-24 01:18PM	Mereo BioPharma Stock Climbs Following Jefferies' Buy Rating, Upside Potential of 89% (GuruFocus.com) +8.65%
Nov-14-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire) -5.68%
Nov-12-24 07:30AM	Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-16-24 09:06AM	Is Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds? (Insider Monkey)
Sep-18-24 08:21AM	Mereo BioPharma Group plc (MREO): A Bull Case Theory (Insider Monkey) +6.84%
Sep-12-24 05:35PM	Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference (GlobeNewswire) -5.79%
Aug-13-24 08:00AM	Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-15-24 11:42PM	Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount (Investing.com)
Jun-14-24 07:50AM	Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market (GlobeNewswire) +6.52%
Jun-12-24 07:45AM	Ultragenyx, Mereo drug reduces fractures in bone disorder study (BioPharma Dive) +8.81%
Jun-11-24 05:47PM	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-30-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.90%
May-15-24 04:01PM	Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +7.09%
Apr-12-24 09:35AM	MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-03-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 05:27PM	Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results (GuruFocus.com) +10.00%
04:01PM	Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Jan-08-24 07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks)
Oct-23-23 04:01PM	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update (GlobeNewswire) -7.89%
Oct-14-23 04:30PM	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-09-23 08:00AM	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-21-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -5.67%
Sep-07-23 07:30AM	Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update (GlobeNewswire)
Aug-10-23 11:04PM	BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC (GuruFocus.com) -6.30%
Aug-04-23 08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Jul-07-23 07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks) +7.32%
Jul-06-23 08:00AM	Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-31-23 07:00AM	Mereo BioPharma to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 01:43PM	Phase 2 Data from ASTRAEUS Trial of Mereo BioPharmas Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference (GlobeNewswire) -5.47%
May-08-23 12:46PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-05-23 04:06PM	Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market (GlobeNewswire)
Apr-21-23 12:00PM	What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now? (Zacks) -5.72%
Apr-13-23 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference (GlobeNewswire)
Mar-28-23 04:30PM	Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
Mar-21-23 06:30AM	Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease (GlobeNewswire) +16.89%
Feb-08-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-10-23 05:35AM	Positive week for Mereo BioPharma Group plc (NASDAQ:MREO) hedge funds investors who lost 33% over the past year (Simply Wall St.) -7.12%
Nov-15-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +5.92%
Nov-08-22 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-22 04:01PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire) -6.97% -8.76%
Oct-28-22 07:00AM	Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management (GlobeNewswire)
Oct-24-22 04:30PM	Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022 (GlobeNewswire)
Oct-21-22 07:00AM	Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting (GlobeNewswire)
Oct-18-22 11:58AM	Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan (Business Wire)
07:00AM	Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value (GlobeNewswire)
Oct-17-22 07:00AM	Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease (GlobeNewswire)
Oct-03-22 05:00PM	Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders (GlobeNewswire) +7.85%
09:00AM	Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five (Business Wire)
Sep-28-22 09:21AM	Chinese Billionaire Zhang Lei is Selling These 10 Stocks (Insider Monkey)
Sep-26-22 07:00AM	Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board (GlobeNewswire)
Sep-14-22 09:00AM	Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders (Business Wire)
Sep-12-22 08:00AM	Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors (GlobeNewswire)
Sep-09-22 08:22PM	Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR (GlobeNewswire) +5.94%
Aug-31-22 07:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)

Show Previous News

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Co-FounderDr. Denise Vera Scots-Knight Ph.D.

Co-FounderMr. Charles Edward Sermon

Chief Financial OfficerMs. Christine Fox CPA

Chief Scientific OfficerDr. John A. Lewicki Ph.D.

VP & Head of HRMs. Bal Lally

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Mereo Biopharma Group Plc ADR

Upgrade your Finviz experience